Cargando…
Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study
INTRODUCTION: Luteinising hormone-releasing hormone agonist (LHRHa) injections are currently used in the treatment of advanced prostate cancer, but the frequency of injections may represent a burden to patients and healthcare services. The aim of this study was to collect real-world evidence about c...
Autores principales: | Cornford, Philip, Jefferson, Kieran, Cole, Owen, Gilbody, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359994/ https://www.ncbi.nlm.nih.gov/pubmed/32700031 http://dx.doi.org/10.1007/s40487-018-0087-1 |
Ejemplares similares
-
Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty
por: Yoo, Eunjoo, et al.
Publicado: (2023) -
Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study
por: Luo, Xiaoping, et al.
Publicado: (2023) -
Assessment of Two Formulations of Triptorelin in Chinese Patients with Endometriosis: A Phase 3, Randomized Controlled Trial
por: Li, Xiaoyan, et al.
Publicado: (2022) -
Clinical outcome of one-third–dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulation
por: Li, Yu, et al.
Publicado: (2012) -
Synthesis of Triptorelin Lactate Catalyzed by Lipase in Organic Media
por: Zhuang, Hong, et al.
Publicado: (2012)